Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026)

Biocryst Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $461000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 39.27% year-over-year to $461000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 19.51% YoY), and the FY2025 full-year result was $1.4 million, up 11.48% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $461000.0, up from $394000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $461000.0 in Q1 2026, with the low at $306000.0 in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $364000.0 across 5 years, with a median of $335000.0 in 2022.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 131.58% — and 2024, when it decreased 26.95%.
• Biocryst Pharmaceuticals' Depreciation & Amortization (CF) stood at $396000.0 in 2022, then grew by 6.82% to $423000.0 in 2023, then decreased by 26.95% to $309000.0 in 2024, then advanced by 27.51% to $394000.0 in 2025, then grew by 17.01% to $461000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $461000.0 (Q1 2026), $394000.0 (Q4 2025), and $335000.0 (Q3 2025), per Business Quant data.